Kumovis
Kumovis is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Kumovis.
Kumovis is a company.
Key people at Kumovis.
Key people at Kumovis.
Kumovis GmbH is a Munich-based medtech company specializing in 3D printing systems for producing patient-specific medical implants and devices from high-performance polymers like PEEK, PEKK, PPSU, and PLLA.[1][2][3][4] It serves medical device manufacturers, hospitals, and surgeons by enabling decentralized, regulatory-compliant manufacturing of individualized products such as skull implants, spinal probes, and surgical instruments, solving challenges in customization, contamination control, and resource efficiency.[1][2][3][5] The company's flagship product, the Kumovis R1 printer, features an integrated clean-room environment via a unique air filtration system, allowing cost-effective, on-site production with mechanical properties comparable to injection-molded parts; growth includes a Series A funding round led by Renolit and Solvay, a U.S. subsidiary launch, and acquisition by 3D Systems.[1][4][8][10]
Kumovis was founded in 2017 at the Technical University of Munich by five alumni spanning medical, plastics engineering, and related fields, including co-founder and co-director Dr. Ing. Miriam Haerst.[2][3] The idea emerged from research in space and medicine on high-performance plastics, aiming to enable additive manufacturing of plastic implants using established medical polymers that were previously difficult to 3D print with required ductility and sterility.[1][2][6] Early traction came swiftly: in 2018, Kumovis won the Formnext Startup Challenge; by 2019, it launched the R1 printer—the world's first with integrated clean-room technology—backed by High-Tech Gründerfonds investment and later Series A funding.[1][4][9] Pivotal moments include validating the technology with leading hospitals and medtech firms, leading to its 2023 acquisition by 3D Systems.[3][10]
Kumovis rides the wave of personalized medicine and point-of-care manufacturing, where 3D printing decentralizes production to match patient anatomy via DICOM imaging, addressing rising demand for customized implants amid aging populations and complex surgeries.[2][3][5] Timing aligns with maturing additive manufacturing regulations (e.g., FDA pathways for polymers) and post-pandemic supply chain resilience needs, favoring clean-room tech for sterile, on-site fabrication over centralized factories.[4][8] Market forces like high-performance polymer advancements and partnerships (e.g., with Renolit, 3D Systems) amplify its influence, enabling innovations in resorbable implants, drug-delivery devices, and X-ray-visible polymers while pushing ecosystem-wide adoption in orthopedics, neurosurgery, and spine care.[5][6][10]
Post-acquisition by 3D Systems, Kumovis is poised to scale globally via expanded R1 deployments, U.S. operations, and R&D in bioresorbable materials, drug-eluting implants, and optimized workflows for broader applications like shoulder joints and vertebral replacements.[5][8][10] Trends in AI-driven design, sustainable polymers, and hybrid manufacturing will shape its path, potentially revolutionizing surgical outcomes by slashing production times and costs. As a catalyst in medtech's 3D printing shift, its influence will grow through ecosystem collaborations, tying back to its founding vision of empowering decentralized, patient-tailored care.
